TY  - JOUR
U1  - Zeitschriftenartikel, wissenschaftlich - begutachtet (reviewed)
A1  - Schuhmacher, Alexander
A1  - Gassmann, Oliver
A1  - Kuss, Michael
A1  - Hinder, Markus
T1  - The art of virtualizing pharma R&D
JF  - Drug discovery today
N2  - Today, virtualizing pharma R&D is increasingly related with data analytics and artificial intelligence (AI), technologies that have been developed by software companies outside the healthcare sector. The process of virtualizing pharma R&D is closely related to the technological advancements that result in the generation of large data sets ranging from genomics, proteomics, metabolomics, medical imaging, IoT wearables and large clinical trials, making it necessary for pharma companies to find new ways to store and ultimately analyze information. As a consequence, pharma companies are experimenting with AI in R&D ranging from in-silico drug design to clinical trail participants identification or dosage error reduction.
Y1  - 2019
U6  - https://doi.org/10.1016/j.drudis.2019.07.004
DO  - https://doi.org/10.1016/j.drudis.2019.07.004
VL  - 24
IS  - 11
SP  - 2105
EP  - 2107
S1  - 3
PB  - Elsevier
CY  - Amsterdam
ER  -